ArticleInternational journal of clinical oncology2026
Re-evaluating the neutropenia-survival paradigm in irinotecan-based therapy for advanced gastric cancer: post-hoc analysis of the RINDBeRG trial.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundChemotherapy-induced neutropenia (CIN) has been considered a favorable prognostic marker across multiple cytotoxic regimens for gastrointestinal malignancies. However, its prognostic relevance in irinotecan (IRI)-based therapy for advanced gastric cancer (AGC) remains unclear.
methodsThis post-hoc analysis used data from the phase III RINDBeRG trial comparing ramucirumab (RAM) plus IRI with IRI monotherapy as third- or later-line treatment for RAM-refractory AGC. Overall survival (OS) was evaluated according to the occurrence of grade 3 or higher neutropenia, defined as CIN. OS was also evaluated according to the baseline absolute neutrophil count (ANC), stratified by quartile-based cutoffs.
resultsAmong the 393 patients in the safety population, 44.5% and 28.5% in the RAM + IRI and IRI arms developed CIN, respectively. Baseline characteristics were generally comparable, with some imbalances across baseline ANC groups. In the RAM + IRI arm, those with and without CIN had a median OS of 9.7 and 8.9 months, respectively (HR = 0.84; 95% CI, 0.62-1.13; p = 0.25). In the IRI arm, those with and without CIN had a median OS of 8.4 and 8.6 months, respectively (HR = 0.85; 95% CI, 0.60-1.19; p = 0.34). Higher baseline ANC was associated with shorter OS, particularly in the RAM + IRI arm (7.3 vs. 10.9 months; HR = 1.83; 95% CI 1.14-2.94; p = 0.01).
conclusionsUnlike other cytotoxic regimens, CIN was not associated with survival in AGC patients receiving IRI with or without RAM. The clinical relevance of baseline ANC warrants further investigation.
trial registrationjRCT2031200106.
Indexed as
Identifiers
42905384What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.